Market Cap 712.09M
Revenue (ttm) 0.00
Net Income (ttm) -95.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.25
Volume 1,649,600
Avg Vol 1,505,912
Day's Range N/A - N/A
Shares Out 172.84M
Stochastic %K 94%
Beta 0.46
Analysts Strong Sell
Price Target $10.31

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300, Langhorne, United States
Richterscale
Richterscale Oct. 24 at 3:55 PM
$SVRA Big buys coming in !
0 · Reply
Zeffanator2
Zeffanator2 Oct. 24 at 11:22 AM
$SVRA I know something. This keeps going up daily.
0 · Reply
keypatience
keypatience Oct. 23 at 11:10 PM
0 · Reply
TeeMan123
TeeMan123 Oct. 23 at 1:51 PM
$SVRA who knows something!!?!?!? This thing is just marching higher and higher off of no news.
0 · Reply
anachartanalyst
anachartanalyst Oct. 23 at 12:02 PM
$SVRA https://anachart.com/wp-content/uploads/ana_temp/1761220902_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 11:26 AM
JMP Securities has updated their rating for Savara ( $SVRA ) to Market Outperform with a price target of 11.
0 · Reply
Zeffanator2
Zeffanator2 Oct. 22 at 12:03 PM
$SVRA It’s SVRA’s time.
0 · Reply
JambaPotato
JambaPotato Oct. 21 at 12:21 PM
$SVRA No thanks on a buyout, not with near term price targets +10 and longer term value appreciation.
1 · Reply
Richterscale
Richterscale Oct. 20 at 8:25 PM
$SVRA hopefully a buyout
0 · Reply
kshonstocks
kshonstocks Oct. 20 at 6:40 PM
$SVRA acts right
0 · Reply
Latest News on SVRA
Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 8 days ago

Savara Announces Chief Medical Officer (CMO) Transition


Savara: Back On Track With Upcoming APAP BLA Filing

Oct 9, 2025, 7:42 AM EDT - 16 days ago

Savara: Back On Track With Upcoming APAP BLA Filing


Savara Announces New Employment Inducement Grant

Jul 18, 2025, 4:05 PM EDT - 3 months ago

Savara Announces New Employment Inducement Grant


Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Apr 21, 2025, 11:16 AM EDT - 6 months ago

Savara: Make-It-Or-Break-It Molbreevi BLA Filing


Richterscale
Richterscale Oct. 24 at 3:55 PM
$SVRA Big buys coming in !
0 · Reply
Zeffanator2
Zeffanator2 Oct. 24 at 11:22 AM
$SVRA I know something. This keeps going up daily.
0 · Reply
keypatience
keypatience Oct. 23 at 11:10 PM
0 · Reply
TeeMan123
TeeMan123 Oct. 23 at 1:51 PM
$SVRA who knows something!!?!?!? This thing is just marching higher and higher off of no news.
0 · Reply
anachartanalyst
anachartanalyst Oct. 23 at 12:02 PM
$SVRA https://anachart.com/wp-content/uploads/ana_temp/1761220902_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 11:26 AM
JMP Securities has updated their rating for Savara ( $SVRA ) to Market Outperform with a price target of 11.
0 · Reply
Zeffanator2
Zeffanator2 Oct. 22 at 12:03 PM
$SVRA It’s SVRA’s time.
0 · Reply
JambaPotato
JambaPotato Oct. 21 at 12:21 PM
$SVRA No thanks on a buyout, not with near term price targets +10 and longer term value appreciation.
1 · Reply
Richterscale
Richterscale Oct. 20 at 8:25 PM
$SVRA hopefully a buyout
0 · Reply
kshonstocks
kshonstocks Oct. 20 at 6:40 PM
$SVRA acts right
0 · Reply
Zeffanator2
Zeffanator2 Oct. 20 at 6:22 PM
$SVRA Mission Control, can you confirm near future blast off?
0 · Reply
KPMD
KPMD Oct. 20 at 4:31 PM
$SVRA with low volume, the stock is moving rapidly up. In my humble opinion that are only two reasons for this one is a short covering rally. The second is a and institution is taking a position in the stock.
3 · Reply
AdamGuzman1961
AdamGuzman1961 Oct. 18 at 1:24 AM
$SSD $SVRA Rapid pullback https://stocktwits.com/AnthonyKline9852/message/632824867
0 · Reply
Flydown
Flydown Oct. 17 at 1:12 PM
$SVRA Savara announces transition of CMO means only one thing as they MOLBREEVI clinical program is they only one in them pipeline SVRA =certain Phase 3 approval!
0 · Reply
Zeffanator2
Zeffanator2 Oct. 16 at 5:31 PM
$SVRA Come Little Mcsqueezy!!!! Waiting for liftoff!!!!
0 · Reply
Smellmahass
Smellmahass Oct. 14 at 7:28 PM
$SVRA Is that phase 3 data that will be presented on October 3st a binary event? or is it already priced in?
2 · Reply
ckruel
ckruel Oct. 14 at 2:03 PM
$SVRA LifeSci Capital analyst Francois Brisebois initiated coverage of Savara (SVRA) with an Outperform rating and $11 price target
1 · Reply
Spacemonkey1
Spacemonkey1 Oct. 9 at 5:54 PM
$SVRA did they give any time frame other than quarter 4 for the new BLA submission?
1 · Reply
justiceforb_85
justiceforb_85 Sep. 30 at 1:27 AM
$SVRA would be a good buyout for $INSM.
0 · Reply
Spacemonkey1
Spacemonkey1 Sep. 29 at 1:27 PM
$SVRA more good news for FDA, though hard to gauge what’s going on at the FDA currently, as they are not trustworthy or reliable at this point,
0 · Reply
G101SPM
G101SPM Sep. 29 at 9:44 AM
$SVRA $3.52 bid. HOLDING LONG POSITION BRIEF: Savara presents new data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 Poster Summary: DLco% (a measure of pulmonary gas transfer) was chosen as the primary endpoint in the IMPALA-2 Phase 3 clinical trial because it is a standardized measure of pulmonary gas transfer widely used in clinical practice Previous research has shown that changes in DLco% correlate with changes in aPAP disease severity (i.e., surfactant accumulation/burden) and may predict the need for whole-lung lavage Post-hoc correlation analyses of IMPALA-2 data were conducted to evaluate the relationship between DLco% and measures of HRQoL, patient functionality, and surfactant burden in patients with aPAP Significant negative correlations were observed between DLco% and measures of respiratory HRQoL (SGRQ Total and Activity scores; higher scores indicate worse quality of life), as well as DLco% and surfactant accumulation (ground-glass opacity scores; lower scores indicate less surfactant) at Week 24. Significant positive correlations were observed between DLco% and patient functionality (exercise capacity expressed as peak METs; higher scores indicate improved exercise capacity) at Weeks 24 and 48 Results further support the clinical relevance of changes in DLco% in aPAP; changes in DLco% are associated with changes in clinical outcomes and the extent of pulmonary pathology, making it a clinically meaningful measure in this rare lung disease
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Sep. 29 at 7:58 AM
$SVRA Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
0 · Reply